HSV-2

Single MHC CTL Epitope Protects Mice From Lethal HSV-2

Published in Vaccine Weekly, November 30th, 1998

Vaccines against herpes simplex virus (HSV) should elicit virus-specific mucosal CD8⁺ cytotoxic T-lymphocytes (CTLs), murine studies suggest.

Joseph E. Blaney Jr., Satvir S. Tevethia, and colleagues of Pennsylvania State University, Hershey, Pennsylvania, report experiments in which mice were vaccinated with genetically engineered adenovirus expressing a single major histocompatibility complex (MHC) class I-restricted CTL recognition epitope cross reactive for HSV-2 and HSV-1. The mice then were intranasally challenged with a lethal dose of HSV-2.

"Development of the ... CTL response conferred resistance in 60 to 75 percent of mice...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1998-11-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry